96 related articles for article (PubMed ID: 27600385)
1. Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years.
Thalange N; Bereket A; Jensen LB; Hiort LC; Peterkova V
Diabetes Ther; 2016 Dec; 7(4):713-724. PubMed ID: 27600385
[TBL] [Abstract][Full Text] [Related]
2. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
[TBL] [Abstract][Full Text] [Related]
4. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
[TBL] [Abstract][Full Text] [Related]
5. A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects.
Ono Y; Nishida T; Hyllested-Winge J; Seino H; Sasaki T
Diabetol Int; 2016 Dec; 7(4):404-412. PubMed ID: 30603293
[TBL] [Abstract][Full Text] [Related]
6. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
[TBL] [Abstract][Full Text] [Related]
7. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes.
Holmberg H; Mersebach H; Kanc K; Ludvigsson J;
Diabet Med; 2008 Jul; 25(7):792-7. PubMed ID: 18644065
[TBL] [Abstract][Full Text] [Related]
9. The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Biester T; von dem Berge T; Bendtsen LQ; Bendtsen MD; Rathor N; Danne T; Haahr H
Pediatr Diabetes; 2020 Aug; 21(5):781-790. PubMed ID: 32306477
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
Herrera KM; Rosenn BM; Foroutan J; Bimson BE; Al Ibraheemi Z; Moshier EL; Brustman LE
Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
[TBL] [Abstract][Full Text] [Related]
11. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
[TBL] [Abstract][Full Text] [Related]
12. Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.
Bowering K; Rodbard HW; Russell-Jones D; Bode B; Harris S; Piletic M; Heller S; Woo V; Babu V; Dethlefsen C; Mathieu C
Diabetes Ther; 2019 Feb; 10(1):177-188. PubMed ID: 30547388
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve study.
Wangnoo SK; Ghosal S; Akhtar S; Shetty R; Tripathi S
Indian J Endocrinol Metab; 2014 Sep; 18(5):715-20. PubMed ID: 25285292
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
[TBL] [Abstract][Full Text] [Related]
16. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
[TBL] [Abstract][Full Text] [Related]
17. Clinical safety of insulin detemir in patients with Type 2 diabetes in the Gulf countries: The multicenter, noninterventional, open-label LevSafe study.
El Shiekh AR; Farrag HA; Ashour T; Alshali KZ; AbdelFattah W
Indian J Endocrinol Metab; 2016; 20(4):443-50. PubMed ID: 27366709
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of insulin detemir: a systematic review.
Suh DC; Aagren M
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):641-55. PubMed ID: 21961796
[TBL] [Abstract][Full Text] [Related]
19. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
[TBL] [Abstract][Full Text] [Related]
20. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.
Takahashi H; Nishimura R; Onda Y; Ando K; Tsujino D; Utsunomiya K
Expert Opin Pharmacother; 2017 Mar; 18(4):335-342. PubMed ID: 28234565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
